{"protocolSection": {"identificationModule": {"nctId": "NCT00669279", "orgStudyIdInfo": {"id": "8COG11059"}, "organization": {"fullName": "University of Florida", "class": "OTHER"}, "briefTitle": "Effect of Carvedilol Controlled-Release (CR) and Atenolol on Central Blood Pressure", "officialTitle": "Non-Invasive Determination of Central Aortic Blood Pressure in Hypertensive Patients Treated With Controlled-Release Carvedilol or Atenolol"}, "statusModule": {"statusVerifiedDate": "2017-09", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2008-04"}, "primaryCompletionDateStruct": {"date": "2010-07", "type": "ACTUAL"}, "completionDateStruct": {"date": "2010-07", "type": "ACTUAL"}, "studyFirstSubmitDate": "2008-04-28", "studyFirstSubmitQcDate": "2008-04-29", "studyFirstPostDateStruct": {"date": "2008-04-30", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2011-12-05", "resultsFirstSubmitQcDate": "2012-02-17", "resultsFirstPostDateStruct": {"date": "2012-03-23", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2017-09-06", "lastUpdatePostDateStruct": {"date": "2017-10-05", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "University of Florida", "class": "OTHER"}, "collaborators": [{"name": "GlaxoSmithKline", "class": "INDUSTRY"}]}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": false, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "The purpose of this research study is to determine whether atenolol or controlled release carvedilol lower blood pressure in the body as effectively as in the arm. Blood pressure measured in the aorta, a large blood vessel carrying blood away from the heart, may be a better measure of the harmful effects of high blood pressure on the body's organs. In the past, blood pressure has only been measured in the arms. However, blood pressure in the arms may not accurately reflect the blood pressure in the aorta and thus may mislead doctors treating high blood pressure. For this reason, we are testing whether two different medications for blood pressure, both in a class called beta blockers, have similar effects on blood pressure in the arm and aorta.", "detailedDescription": "Carvedilol reduces aortic wave reflection and improves left ventricular/vascular coupling: a comparison with atenolol (CENTRAL Study) is a prospective, open-label, comparative, randomized control trial that evaluated brachial and central hemodynamic profiles in patients taking atenolol or controlled-release carvedilol."}, "conditionsModule": {"conditions": ["Hypertension"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "SINGLE", "whoMasked": ["OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 41, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Carvedilol CR", "type": "EXPERIMENTAL", "interventionNames": ["Drug: Carvedilol CR"]}, {"label": "Atenolol", "type": "EXPERIMENTAL", "interventionNames": ["Drug: Atenolol"]}], "interventions": [{"type": "DRUG", "name": "Carvedilol CR", "description": "Dose titration of 20mg by mouth once daily for 1 week, then 40mg by mouth once daily for 1 week, then 80mg by mouth once daily for 2 weeks", "armGroupLabels": ["Carvedilol CR"], "otherNames": ["Coreg CR"]}, {"type": "DRUG", "name": "Atenolol", "description": "Dose titration of 25mg by mouth once daily for 1 week, then 50mg by mouth once daily for 1 week, then 100mg by mouth once daily for 2 weeks", "armGroupLabels": ["Atenolol"], "otherNames": ["Tenormin"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Central Aortic Blood Pressure", "timeFrame": "Measured at baseline and 4 weeks."}], "secondaryOutcomes": [{"measure": "Peripheral Blood Pressure", "timeFrame": "Measured at baseline, 2 weeks, and 4 weeks."}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* At least 18 years of age\n* Hypertension (untreated or treated with no more then one anti-hypertensive drug)\n\nExclusion Criteria:\n\n* Secondary forms of hypertension (including sleep apnea)\n* Patients currently treated with two or more antihypertensive drugs\n* Patients taking antihypertensive drugs with properly measured clinic systolic blood pressure greater then 170mmHg\n* Isolated systolic hypertension\n* Other diseases requiring treatment with blood pressure lowering medications\n* Heart rate less then 55 beats/min (in the absence of beta-blocker therapy)\n* Known cardiovascular disease including history of angina pectoris, heart failure, presence of a cardiac pacemaker, history of myocardial infarction or revascularization procedure, or cerebrovascular disease (including stroke and TIA)\n* Known diabetes mellitus (Type 1 or 2)\n* Renal insufficiency defined as a serum creatinine greater then 1.5mg/dL in males and 1.4mg/dL in females\n* Primary renal disease\n* Pregnancy or lactation\n* History of Raynaud's syndrome\n* Alcoholism and recreational drug use (due to compliance concerns)", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Benjamin Epstein, Pharm.D.", "affiliation": "University of Florida", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "University of Florida", "city": "Gainesville", "state": "Florida", "zip": "32610", "country": "United States", "geoPoint": {"lat": 29.65163, "lon": -82.32483}}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Carvedilol CR", "description": "Controlled-release carvedilol 20 mg - Forced titration occurred in carvedilol to 40 mg at week one, and to 80 mg at week two."}, {"id": "FG001", "title": "Atenolol", "description": "Atenolol 25 mg once daily - Forced titration occurred in atenolol to 50 mg at week one, and to 100 mg at week two."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "22"}, {"groupId": "FG001", "numSubjects": "19"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "22"}, {"groupId": "FG001", "numSubjects": "19"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Carvedilol CR", "description": "Controlled-release carvedilol 20 mg - Forced titration occurred in carvedilol to 40 mg at week one, and to 80 mg at week two."}, {"id": "BG001", "title": "Atenolol", "description": "Atenolol 25 mg once daily - Forced titration occurred in atenolol to 50 mg at week one, and to 100 mg at week two."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "22"}, {"groupId": "BG001", "value": "19"}, {"groupId": "BG002", "value": "41"}]}], "measures": [{"title": "Age, Categorical", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "<=18 years", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Between 18 and 65 years", "measurements": [{"groupId": "BG000", "value": "22"}, {"groupId": "BG001", "value": "19"}, {"groupId": "BG002", "value": "41"}]}, {"title": ">=65 years", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}]}]}, {"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "47.7", "spread": "13.1"}, {"groupId": "BG001", "value": "46.1", "spread": "9.9"}, {"groupId": "BG002", "value": "46.9", "spread": "11.5"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "13"}, {"groupId": "BG001", "value": "13"}, {"groupId": "BG002", "value": "26"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "9"}, {"groupId": "BG001", "value": "6"}, {"groupId": "BG002", "value": "15"}]}]}]}, {"title": "Region of Enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "United States", "categories": [{"measurements": [{"groupId": "BG000", "value": "22"}, {"groupId": "BG001", "value": "19"}, {"groupId": "BG002", "value": "41"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Central Aortic Blood Pressure", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmHg", "timeFrame": "Measured at baseline and 4 weeks.", "groups": [{"id": "OG000", "title": "Carvedilol CR", "description": "Controlled-release carvedilol 20 mg - Forced titration occurred in carvedilol to 40 mg at week one, and to 80 mg at week two."}, {"id": "OG001", "title": "Atenolol", "description": "Atenolol 25 mg once daily - Forced titration occurred in atenolol to 50 mg at week one, and to 100 mg at week two."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "22"}, {"groupId": "OG001", "value": "19"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-16.1", "spread": "10.4"}, {"groupId": "OG001", "value": "-16.0", "spread": "18.7"}]}]}]}, {"type": "SECONDARY", "title": "Peripheral Blood Pressure", "reportingStatus": "NOT_POSTED", "timeFrame": "Measured at baseline, 2 weeks, and 4 weeks.", "denomUnitsSelected": "Participants"}]}, "adverseEventsModule": {"frequencyThreshold": "0", "eventGroups": [{"id": "EG000", "title": "Carvedilol CR", "description": "Controlled-release carvedilol 20 mg - Forced titration occurred in carvedilol to 40 mg at week one, and to 80 mg at week two.", "seriousNumAffected": 0, "seriousNumAtRisk": 22, "otherNumAffected": 0, "otherNumAtRisk": 22}, {"id": "EG001", "title": "Atenolol", "description": "Atenolol 25 mg once daily - Forced titration occurred in atenolol to 50 mg at week one, and to 100 mg at week two.", "seriousNumAffected": 0, "seriousNumAtRisk": 19, "otherNumAffected": 0, "otherNumAtRisk": 19}]}, "moreInfoModule": {"limitationsAndCaveats": {"description": "Small sample size, short duration."}, "certainAgreement": {"piSponsorEmployee": false, "restrictiveAgreement": false}, "pointOfContact": {"title": "Dr. Benjamin J Epstein", "organization": "University of Florida", "email": "epstein@cop.ufl.edu", "phone": "3523590945"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-26"}, "conditionBrowseModule": {"meshes": [{"id": "D000006973", "term": "Hypertension"}], "ancestors": [{"id": "D000014652", "term": "Vascular Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M10024", "name": "Hypertension", "asFound": "Hypertension", "relevance": "HIGH"}, {"id": "M17400", "name": "Vascular Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000001262", "term": "Atenolol"}, {"id": "D000077261", "term": "Carvedilol"}], "ancestors": [{"id": "D000000319", "term": "Adrenergic beta-Antagonists"}, {"id": "D000018674", "term": "Adrenergic Antagonists"}, {"id": "D000018663", "term": "Adrenergic Agents"}, {"id": "D000018377", "term": "Neurotransmitter Agents"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000000959", "term": "Antihypertensive Agents"}, {"id": "D000000975", "term": "Antioxidants"}, {"id": "D000020011", "term": "Protective Agents"}, {"id": "D000002121", "term": "Calcium Channel Blockers"}, {"id": "D000049990", "term": "Membrane Transport Modulators"}, {"id": "D000077264", "term": "Calcium-Regulating Hormones and Agents"}, {"id": "D000014665", "term": "Vasodilator Agents"}, {"id": "D000058668", "term": "Adrenergic alpha-1 Receptor Antagonists"}, {"id": "D000000317", "term": "Adrenergic alpha-Antagonists"}, {"id": "D000000889", "term": "Anti-Arrhythmia Agents"}, {"id": "D000013565", "term": "Sympatholytics"}, {"id": "D000001337", "term": "Autonomic Agents"}, {"id": "D000018373", "term": "Peripheral Nervous System Agents"}, {"id": "D000058671", "term": "Adrenergic beta-1 Receptor Antagonists"}], "browseLeaves": [{"id": "M1718", "name": "Carvedilol", "asFound": "Depressive Disorder", "relevance": "HIGH"}, {"id": "M4568", "name": "Atenolol", "asFound": "Instructor", "relevance": "HIGH"}, {"id": "M3671", "name": "Adrenergic beta-Antagonists", "relevance": "LOW"}, {"id": "M20746", "name": "Adrenergic Agents", "relevance": "LOW"}, {"id": "M20755", "name": "Adrenergic Antagonists", "relevance": "LOW"}, {"id": "M20504", "name": "Neurotransmitter Agents", "relevance": "LOW"}, {"id": "M4277", "name": "Antihypertensive Agents", "relevance": "LOW"}, {"id": "M4292", "name": "Antioxidants", "relevance": "LOW"}, {"id": "M21869", "name": "Protective Agents", "relevance": "LOW"}, {"id": "M5398", "name": "Calcium, Dietary", "relevance": "LOW"}, {"id": "M5381", "name": "Calcium", "relevance": "LOW"}, {"id": "M5384", "name": "Calcium Channel Blockers", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M17412", "name": "Vasodilator Agents", "relevance": "LOW"}, {"id": "M29194", "name": "Adrenergic alpha-1 Receptor Antagonists", "relevance": "LOW"}, {"id": "M3669", "name": "Adrenergic alpha-Antagonists", "relevance": "LOW"}, {"id": "M4213", "name": "Anti-Arrhythmia Agents", "relevance": "LOW"}, {"id": "M16344", "name": "Sympatholytics", "relevance": "LOW"}, {"id": "M29197", "name": "Adrenergic beta-1 Receptor Antagonists", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AnAg", "name": "Antihypertensive Agents"}, {"abbrev": "ChanBlk", "name": "Channel Blockers"}, {"abbrev": "VaDiAg", "name": "Vasodilator Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "AnArAg", "name": "Anti-Arrhythmia Agents"}, {"abbrev": "BDCA", "name": "Bone Density Conservation Agents"}]}}, "hasResults": true}